The GLP-1 market has fundamentally reshaped the pharmaceutical industry over the past five years. Ozempic by Novo Nordisk has emerged as a global blockbuster, generating billions in annual revenue and transforming the treatment landscape for type 2 diabetes and obesity. But as with every highly protected innovation,
